SLx-2101, A Novel Long Acting PDE-5 Inhibitor for Disorders Related to
                           Endothelial Dysfunction

    BOSTON, Oct. 11 /PRNewswire/ -- Surface Logix today announced the
successful completion of the first clinical trial for SLx-2101. The Phase I
study was designed to assess the safety and tolerability of SLx-2101,
establish the pharmacokinetic (PK) profile and to provide evidence of activity
in two pharmacodynamic (PD) models. The results of this study will be
presented by noted urologist and recognized expert on sexual health, Dr. Irwin
Goldstein, at the upcoming Sexual Medicine Society of North America, Inc.
(SMSNA) meeting in New York City from November 17-20.
    "The initial Phase I trial indicated that SLx-2101 was safe, well
tolerated and pharmacodynamicaly active," notes Dr. William Prince, Chief
Development Officer. "We were particularly pleased to find that the PK profile
more than met our expectations for SLx-2101 and we look forward to sharing
these results with our peers in November."
    In a double-blind, placebo controlled, randomized study, healthy male
volunteers received single oral doses of SLx-2101 or placebo. Five dose levels
were included and subjects were monitored for adverse events and
pharmacokinetic sampling was performed out to 48 hours post dose. Two methods
of assessing pharmacodynamic activity were included in the study. Erectile
response was assessed over 24 hours using the Rigiscan(TM) Plus system and
peripheral arterial tone was assessed using the Endo-PAT2000(TM) device.
    The results from the trial confirm the ability of the Pharmacomer(TM)
Technology Platform to design specific pharmacokinetic performance into a
molecule while optimizing potency and selectivity. The design of SLx-2101 and
its preclinical program was directed to differentiate SLx-2101 from other PDE5
inhibitors based on the combined features of potency and duration of action in
excess of 24 hours. The development plan for SLx-2101 includes a number of
conditions related to endothelial dysfunction including male erectile
dysfunction (MED), pulmonary arterial hypertension (PAH), and congestive heart
failure (CHF).

    About SLx-2101 and Endothelial Dysfunction
    SLx-2101 is an oral phosphodiesterase-5 (PDE-5) inhibitor designed using
Surface Logix' proprietary small molecule Pharmacomer(TM) Technology.  SLx-
2101 is being developed to treat endothelial dysfunction, a physiological
disability of endothelial cells, the cells that line the inner surface of all
blood vessels, arteries and veins, that prevents them from carrying out their
normal biochemical functions. Normal endothelial cells are involved in
mediating the processes of coagulation, platelet adhesion, immune function,
control of volume and electrolyte content of the intravascular and
extravascular spaces.  Endothelial dysfunction is believed to be the
underlying cause for several major diseases including atherosclerosis,
congestive heart failure, hypertension and erectile dysfunction.

    About Surface Logix Inc.
    Surface Logix Inc uses its expertise in biophysical chemistry to create
new small molecule drugs that are optimized to meet the challenges of human
physiology. The company is advancing multiple internal programs focused
primarily on cardiovascular disease, oncology and metabolic disorders and
works with strategic partners to create differentiated new chemical entities.

     Contact:
     David H. Donabedian, Ph.D.
     Vice President, Business Development
     617.746.8520

     Media:
     Kari Watson
     MacDougall Biomedical Communications Inc.
     508.647.0209

Link to this page: